Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib.

Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib. Arch Soc Esp Oftalmol. 2019 Jan 31;: Authors: Moruno-Rodríguez A, Sánchez-Vicente JL, Rueda-Rueda T, Lechón-Caballero B, Muñoz-Morales A, López-Herrero F Abstract A 30 year-old man with acute myeloblastic leukaemia and secondary myelodysplastic syndrome developed graft-versus-host disease. The patient was treated with ruxolitinib. After being treated for 3 months with ruxolitinib, an inhibitor of Janus kinase, he developed Aspergillus retinal necrosis resistant to common treatment. Treatment with Janus kinase inhibitors may lead to an increased incidence of opportunistic infections. Janus kinase inhibitor administration may result in poor treatment efficacy. PMID: 30712951 [PubMed - as supplied by publisher]
Source: Archivos de la Sociedad Espanola de Oftalmologia - Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research